zalcitabine has been researched along with T-Cell Lymphoma in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Irons, RD; Le, AT; Som, DB; Stillman, WS | 1 |
Buckley, LA; Collins, BJ; Foley, JF; Giles, HD; Heath, JE; May, RD; Rao, GN | 1 |
Cochran, C; Goodrow, T; Söderkvist, P; Wiseman, RW; Zhuang, SM | 1 |
Cinatl, J; Doerr, HW; Driever, PH; Gröschel, B; Kabickova, H; Kornhuber, B; Kotchetkov, R; Schwabe, D | 1 |
4 other study(ies) available for zalcitabine and T-Cell Lymphoma
Article | Year |
---|---|
2'3'-Dideoxycytidine-induced thymic lymphoma correlates with species-specific suppression of a subpopulation of primitive hematopoietic progenitor cells in mouse but not rat or human bone marrow.
Topics: Adult; Animals; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Interleukin-3; Lymphoma, T-Cell; Male; Mice; Mice, Inbred C57BL; Rats; Recombinant Proteins; Species Specificity; Stem Cell Factor; Thymus Neoplasms; Zalcitabine | 1995 |
Carcinogenicity of 2',3'-dideoxycytidine in mice.
Topics: Anemia; Animals; Anti-HIV Agents; Atrophy; Body Weight; Carcinogenicity Tests; CD4-CD8 Ratio; Female; Lymphoma, T-Cell; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Sex Factors; Species Specificity; Thymus Gland; Thymus Neoplasms; Time Factors; Tumor Suppressor Protein p53; Zalcitabine | 1996 |
Genetic alterations of p53 and ras genes in 1,3-butadiene- and 2',3'-dideoxycytidine-induced lymphomas.
Topics: Animals; Blotting, Southern; Butadienes; Carcinogens; Genes, p53; Genes, ras; Lymphoma, T-Cell; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Polymorphism, Single-Stranded Conformational; Zalcitabine | 1997 |
Azidothymidine resistance of H9 human T-cell lymphoma cells is associated with decreased sensitivity to antitumor agents and inhibition of apoptosis.
Topics: Anti-HIV Agents; Antimetabolites; Antineoplastic Agents; Apoptosis; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |